Head of Investor Relations
TriSalus Life Sciences, Inc. (TLSI)Board Member
Phoenix Motor Inc. (PEVM)Equibles does not estimate personal net worth.
Get an email with a short summary when TriSalus Life Sciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get TLSI alertsJames Young is recorded as CFO at TriSalus Life Sciences, Inc. (TLSI) since January 6, 2025, Head of Investor Relations at TriSalus Life Sciences, Inc. (TLSI) and Board Member at Phoenix Motor Inc. (PEVM). The newest filing on record that lists James Young as Head of Investor Relations at TriSalus Life Sciences, Inc. (TLSI) is dated July 19, 2024. The newest filing on record that lists James Young as Board Member at Phoenix Motor Inc. (PEVM) is dated December 1, 2025. TriSalus Life Sciences, Inc. reported in an 8-K filed May 30, 2025 that James Young resigned as Chief Financial Officer, effective May 30, 2025. TriSalus Life Sciences, Inc. reported in an 8-K filed January 8, 2025 that James Young was appointed Chief Financial Officer, Secretary, Treasurer and principal financial and accounting officer, effective January 6, 2025. Phoenix Motor Inc. reported in an 8-K filed May 20, 2024 that James Young was appointed members of the board of directors of the Company, effective May 16, 2024. James Young has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for TriSalus Life Sciences, Inc. on September 14, 2026. TriSalus Life Sciences, Inc. is classified in the Medical Devices industry within the Healthcare sector. Phoenix Motor Inc. is classified in the Auto Manufacturers industry within the Consumer Cyclical sector. Other leadership on record at TriSalus Life Sciences, Inc. includes Mary Szela (CEO and Board Member), Karim Karti (Chairman), Mats Wahlström (Chairman and Board Member) and 7 others.
“On May 23, 2025, TriSalus Life Sciences, Inc. (the "Company") and James Young, the Company's Chief Financial Officer, entered into an Agreement and Release (the "Agreement") whereby Mr. Young resigned from the Company for personal reasons, effective May 30, 2025.”
“On January 4, 2025, the Board of Directors (the "Board") of TriSalus Life Sciences, Inc. (the "Company") approved, effective January 6, 2025, a leadership transition, promoting James Young to Chief Financial Officer, Secretary, Treasurer and principal financial and accounting officer of the Company, and appointing Sean Murphy to Chief Manufacturing, Strategy and Business Development Officer.”
“Good afternoon, and thanks for joining us to have a conversation with Mary Zella, president and CEO, and David Patience, CFO of Trisalus Life Sciences.”
“I am pleased to announce that TriSalus achieved the following results in the first quarter that ended March 31st of 2025. Our revenue, solely driven by the success of the TriNav device in the U.S., reached $9.2 million.”
“Joining me today from TriSalus Life Sciences are Mary Szela, President and Chief Executive Officer; Sean Murphy, Chief Financial Officer; and Dr. Steven Katz, Chief Medical Officer.”
2025-01-06–present
Start not stated–present
Last confirmed July 19, 2024
Start not stated–present
Last confirmed December 1, 2025
2025-01-06–2025-05-30
Start not stated–2025-05-30
Medical Devices · Healthcare
Head of Investor Relations, CFO
2025-01-06–present
